The National Heart, Lung and Blood Institute (NHLBI) has awarded a $14,097.60 firm fixed price purchase order to Psomagen Inc., a for-profit organization and manufacturer of goods, to provide transcriptome profiling of human bone marrow core samples. The work supports the Hematology Branch at NHLBI. This is not a set-aside contract.
Psomagen Inc. is a subsidiary of Macrogen, Inc. and operates CLIA-certified and CAP-accredited facilities. The company has a $500 million single-award Indefinite Delivery Vehicle (IDV) contract with NHLBI to establish and operate the Centralized Omics Resource for the Trans-Omics for Precision Medicine (TOPMed) initiative, which enables precision medicine approaches for cardiovascular, lung, blood, and sleep disorders. Psomagen has also received federal grants and contracts from other NIH institutes, the USDA, and the Smithsonian Institution to provide genomic sequencing and analysis services for research on neurodegenerative diseases, cancer, infectious diseases, and agricultural genetics.
Generated 3/6/25, 9:48 AM